Product Information
CLONAZEPAM 0.25 MG ODT is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.4385 per EA under NDC 00093929167. Its NADAC has been published 227 times since Jun 1, 2022.
FDA first approved this application on Aug 10, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.25 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093929167
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLONAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA077194FDA Approved
8/10/2005
TE Code
AB
On Market Since
3/2/2022
Pharmacological Classes
Price Statistics
The NADAC for CLONAZEPAM 0.25 MG ODT has been published 227 times since Jun 1, 2022, and over the history we have for it it has declined 37.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4385 per EA |
|---|---|
| All-time high | $0.7486 (Aug 10, 2022) |
| All-time low | $0.3522 (Jan 17, 2024) |
| 52-week high | $0.6792 |
| 52-week low | $0.4331 |
| Median price | $0.5080 |
| Average price | $0.5291 |
| Largest weekly change | +52.3% (Feb 21, 2024) |
| Weeks tracked | 227 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Clonazepam market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clonazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLONAZEPAM 0.25 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for CLONAZEPAM 0.25 MG ODT, manufactured by Teva Pharmaceuticals USA Inc., is $0.4385 per EA (NDC 00093929167), effective Sep 30, 2026.
How has the price of CLONAZEPAM 0.25 MG ODT changed over time?
Over the history we have for it, the NADAC for CLONAZEPAM 0.25 MG ODT has declined 37.6%. It has been tracked across 227 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for CLONAZEPAM 0.25 MG ODT?
Since Jun 1, 2022, the NADAC for CLONAZEPAM 0.25 MG ODT has ranged from a low of $0.3522 (Jan 17, 2024) to a high of $0.7486 (Aug 10, 2022), with a median of $0.5080 per EA.
Are there cheaper alternatives to CLONAZEPAM 0.25 MG ODT?
No other NADAC-published product currently shares the active ingredient and strength of CLONAZEPAM 0.25 MG ODT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLONAZEPAM 0.25 MG ODT?
CLONAZEPAM 0.25 MG ODT (NDC 00093929167) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.